Anika Therapeutics News

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024

BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its

GlobeNewswireApr 18 16:01 ET

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference

BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the

GlobeNewswireApr 2 08:00 ET

Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

Yahoo FinanceMar 26 09:40 ET

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 16 15:15 ET

Anika Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

Yahoo FinanceMar 15 07:01 ET

Express News | Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $37

Moomoo 24/7Mar 14 10:15 ET

Anika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price Target

TipRanksMar 14 10:15 ET

Express News | Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $22 Price Target

Moomoo 24/7Mar 14 09:55 ET

Anika Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 -8.37% Stephens & Co. → $22 Reiterates Equal-Weight → Equal-Weight 01/03/2024 20.78% Barrington

BenzingaMar 14 09:53 ET

Anika Therapeutics to Reduce Workforce by 9%

Seeking AlphaMar 14 03:10 ET

Earnings Call Summary | Anika Therapeutics(ANIK.US) Q4 2023 Earnings Conference

The following is a summary of the Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript:Financial Performance:Anika reported a Q4 total revenue of $43 million, primarily from growth in U.S.

moomoo AIMar 13 20:07 ET · Conference Call

Anika Therapeutics Conducted Strategic Review, Evaluating Alternatives to Increase Shareholder Value, Including Potential Sale >ANIK

Anika Therapeutics Conducted Strategic Review, Evaluating Alternatives to Increase Shareholder Value, Including Potential Sale >ANIK

Dow JonesMar 13 16:23 ET

Anika Therapeutics: 'Remains Open to All Value Enhancing Opportunities' >ANIK

Anika Therapeutics: 'Remains Open to All Value Enhancing Opportunities' >ANIK

Dow JonesMar 13 16:23 ET

Anika Therapeutics Non-GAAP EPS of $0.05 Beats by $0.28, Revenue of $42.97M Beats by $1.57M

Seeking AlphaMar 13 16:22 ET

Anika Therapeutics to Reduce About 9% of Workforce, Effective End of 1Q >ANIK

Anika Therapeutics to Reduce About 9% of Workforce, Effective End of 1Q >ANIK

Dow JonesMar 13 16:21 ET

Anika Therapeutics: Cost Reduction Initiatives Providing Annual Savings of About $10 M >ANIK

Anika Therapeutics: Cost Reduction Initiatives Providing Annual Savings of About $10 M >ANIK

Dow JonesMar 13 16:20 ET

Anika Therapeutics Positioned to Generate Adj EBITDA of $25 M to $30 M in 2024 >ANIK

Anika Therapeutics Positioned to Generate Adj EBITDA of $25 M to $30 M in 2024 >ANIK

Dow JonesMar 13 16:20 ET

Anika Therapeutics Guides For FY 2024 Revenue of $168-$173 Million, Vs CIQ Analyst Consensus of $179 Million

04:09 PM EDT, 03/13/2024 (MT Newswires) -- Anika Therapeutics Guides For FY 2024 Revenue of $168-$173 Million, vs CIQ Analyst Consensus of $179 Million

MT NewswiresMar 13 16:09 ET

Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q4 Revenue $43M, Vs. Street Est of $41.4M

04:06 PM EDT, 03/13/2024 (MT Newswires) -- Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q4 Revenue $43M, vs. Street Est of $41.4M

MT NewswiresMar 13 16:06 ET

Anika Therapeutics 4Q Adj EPS 5c >ANIK

Anika Therapeutics 4Q Adj EPS 5c >ANIK

Dow JonesMar 13 16:05 ET